LAG3 and neoplasm: The combination of anti-PD-1-CTLA4 in the treatment of prostate cancer is gratifying (42); meanwhile, antagonizing LAG3 and PD1 can enhance tumor-specific cellular response and induce tumor rejection (43, 44).